1. Home
  2. AAT vs REPL Comparison

AAT vs REPL Comparison

Compare AAT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Assets Trust Inc.

AAT

American Assets Trust Inc.

N/A

Current Price

$21.73

Market Cap

1.3B

Sector

Real Estate

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$22.28

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AAT
REPL
Founded
1967
2015
Country
United States
United States
Employees
208
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
AAT
REPL
Price
$21.73
$22.28
Analyst Decision
Sell
Buy
Analyst Count
3
8
Target Price
★ $23.50
$23.33
AVG Volume (30 Days)
384.9K
★ 3.0M
Earning Date
10-27-2026
10-28-2026
Dividend Yield
★ 6.32%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.30
N/A
Revenue
★ $436,204,000.00
N/A
Revenue This Year
$2.49
N/A
Revenue Next Year
$3.76
$513.15
P/E Ratio
$72.12
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$17.72
$1.50
52 Week High
$25.97
$21.91

Technical Indicators

Market Signals
Indicator
AAT
REPL
Relative Strength Index (RSI) 51.73 81.09
Support Level $20.56 $7.11
Resistance Level $21.76 N/A
Average True Range (ATR) 0.60 1.43
MACD 0.06 0.90
Stochastic Oscillator 64.73 96.10

Price Performance

Historical Comparison
AAT
REPL

About AAT American Assets Trust Inc.

American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: